Octreotide is indicated to treat acromegaly (pituitary gland produces too much growth hormone), metastatic carcinoid syndrome and diarrhea associated with vasoactive intestinal peptide-secreting tumor. Octreotide, a cyclic octapeptide agent, inhibits growth hormone, glucagon, and insulin more effectively than the natural hormone, somatostatin. Its suppression of luteinizing hormone's (LH) response to gonadotrophin releasing hormone (GnRH) and inhibition of the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, and pancreatic polypeptide are similar to somatostatin's actions. The drug also reduces growth hormone and/or IGF-I (somatomedin C) in acromegaly, inhibits gallbladder contractions, reduces bile secretion and suppresses the secretion of thyroid stimulating hormone.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL monograph for this compound, just click the ADD TO CART button.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.